ALKYL [2-(2-{5-[4-(4-{2-[1-(2-METHOXYCARBONYLAMINO-ACETYL)-PYRROLIDIN-2-YL]-3H-IMIDAZOL-4-YL}-PHENYL)-BUTA-1,3-DIINYL]-1H-IMIDAZOL-2-YL}-PYRROLIDIN-1-YL)-2-OXO-ETHYL]-CARBAMATE, PHARMACEUTICAL COMPOSITION, MEDICATION, METHOD OF TREATING VIRAL DISEASES Russian patent published in 2014 - IPC C07D403/04 C07D403/14 C07D405/14 A61K31/4178 A61P31/12 

FIELD: chemistry.

SUBSTANCE: invention relates to novel alkyl [2-(2-{5-[4-(4-{2-[1-(2-methoxycarbonylamino-acetyl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-phenyl)-buta-1,3-diinyl]-1H-imidazol-2-yl}-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamates or their naphthalene-1,5-disulfonates, which possess properties of NS5A protein inhibitor and can be used for prevention and treatment of viral diseases, caused by viruses of hepatitis C (HCV) and hepatitis GBV-C. In claimed invention compounds, corresponding to general formula 1 R¹, R², R³ and R⁴ independently on each other stand for C₁-C₃ alkyl; R⁵ and R⁶ independently on each other stand for C₁-C₃alkyloxymethyl, or R³, and R⁵, and R⁴, and R⁶, together with carbon atoms, which they are bound with, independently on each other form tetrahydrofurane cycle.

EFFECT: improved propertied of compounds.

7 cl, 2 tbl, 7 ex